UNSPSC 51401604: Tiapride hydrochloride

This classification denotes an anti-dyskinesia agent C15H24N2O4S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 25N106WEDO, chemically known as benzamide, n-(2-(diethylamino)ethyl)-2-methoxy-5-(methylsulfonyl)-, hydrochloride (1:1), but more generally known as tiapride hydrochloride, which bears US NIH Compound Identifier 5702214. European Medicines Agency schedules Tiapride hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04854MIG.

Most nations, for tariff and trade purposes, schedule tiapride hydrochloride under HS 29242995 and SITC 51479. As of Q4 2014, TIAPRIDE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CCN(CC)CCNC(=O)C1CC(CCC1OC)S(=O)(=O)C.CL.

UNSPSC 51401604 Tiapride hydrochloride is a Commodity code that sits at the bottom tier of the pharmaceutical taxonomy, yet the recent state and local procurement activity under this code shows a marked mismatch between the nominal product and what is actually being solicited. The single recent opportunity indexed to this code—Seminole County, Florida's IFB for Naloxone and Safe Drug Deactivation Systems—involves opioid-reversal agents and harm-reduction equipment, not tiapride hydrochloride, which is an antipsychotic medication used in other clinical contexts. State and local governments do not appear to be actively soliciting tiapride hydrochloride itself through formal competitive procurements at present, and this code shows little relevant recent activity aligned to its name.

Seminole County's July 2026 IFB (IFB60459723LAS, due July 26, 2023) requested 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The solicitation called for electronic bid submission through the county's e-Procurement Portal, included E-Verify and drug-free workplace compliance requirements, and contemplated a two-year initial term with an optional one-year renewal on a fixed-fee basis. The procurement noted potential FEMA funding and associated federal compliance obligations. This opportunity reflects community health and harm-reduction purchasing rather than the pharmaceutical class the code nominally represents, signaling either a coding error in the source data or limited current demand for tiapride hydrochloride through state and local competitive channels.